Compare MX & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MX | JSPR |
|---|---|---|
| Founded | 2003 | 2018 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.8M | 68.4M |
| IPO Year | N/A | N/A |
| Metric | MX | JSPR |
|---|---|---|
| Price | $2.91 | $1.62 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 12 |
| Target Price | $5.75 | ★ $25.60 |
| AVG Volume (30 Days) | 583.4K | ★ 3.6M |
| Earning Date | 11-03-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $224,755,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 14.62 | N/A |
| 52 Week Low | $2.18 | $1.39 |
| 52 Week High | $5.16 | $26.05 |
| Indicator | MX | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 65.83 | 38.79 |
| Support Level | $2.19 | $1.68 |
| Resistance Level | $2.43 | $2.42 |
| Average True Range (ATR) | 0.15 | 0.20 |
| MACD | 0.09 | 0.01 |
| Stochastic Oscillator | 100.00 | 25.25 |
MagnaChip Semiconductor Corp designs and manufactures analog and mixed-signal semiconductor platform solutions for communications, Internet of Things applications, consumer, industrial and automotive applications. The company's product portfolio consists of large display solutions, mobile display solutions, sensor solutions, LED solutions, mobile solutions, and power conversions. The company operates in two segments namely, Transitional Fab 3 foundry services and Standard products business. The company operates in Korea, Asia Pacific (other than Korea), United States and Europe.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.